PetVivo Holdings, Inc. (PETV)
USD 0.63
(4.99%)
USD 0.63
(4.99%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 11.36 Million USD | 24.52% |
| 2023 | 9.12 Million USD | 83.54% |
| 2022 | 4.97 Million USD | 153.51% |
| 2021 | 1.96 Million USD | -0.4% |
| 2020 | 1.96 Million USD | -56.16% |
| 2019 | 4.49 Million USD | 96.39% |
| 2018 | 2.28 Million USD | -86.05% |
| 2017 | 16.39 Million USD | 392.96% |
| 2016 | 3.32 Million USD | 176.75% |
| 2015 | 1.2 Million USD | -96.75% |
| 2014 | 36.97 Million USD | 44769.35% |
| 2013 | 82.4 Thousand USD | -19.53% |
| 2012 | 102.4 Thousand USD | -61.03% |
| 2011 | 262.78 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 11.36 Million USD | 24.52% |
| 2024 Q1 | 2.92 Million USD | 24.48% |
| 2024 Q2 | 3.01 Million USD | 2.81% |
| 2024 Q4 | 2.87 Million USD | 12.91% |
| 2024 Q3 | 2.54 Million USD | -15.42% |
| 2023 Q4 | 2.35 Million USD | -9.7% |
| 2023 Q3 | 2.6 Million USD | 18.71% |
| 2023 Q2 | 2.19 Million USD | 11.34% |
| 2023 Q1 | 1.97 Million USD | 13.59% |
| 2023 FY | 9.12 Million USD | 83.54% |
| 2022 Q2 | 1.1 Million USD | 114.12% |
| 2022 FY | 4.97 Million USD | 153.51% |
| 2022 Q1 | 517.61 Thousand USD | 55.99% |
| 2022 Q3 | 1.6 Million USD | 45.23% |
| 2022 Q4 | 1.73 Million USD | 7.81% |
| 2021 Q2 | 811.03 Thousand USD | 84.13% |
| 2021 Q1 | 440.46 Thousand USD | -12.98% |
| 2021 FY | 1.96 Million USD | -0.4% |
| 2021 Q3 | 377.54 Thousand USD | -53.45% |
| 2021 Q4 | 331.82 Thousand USD | -12.11% |
| 2020 FY | 1.96 Million USD | -56.16% |
| 2020 Q1 | 493.72 Thousand USD | -55.39% |
| 2020 Q2 | 425.76 Thousand USD | -13.76% |
| 2020 Q3 | 543.07 Thousand USD | 27.55% |
| 2020 Q4 | 506.17 Thousand USD | -6.8% |
| 2019 Q1 | 2.09 Million USD | 119.36% |
| 2019 Q4 | 1.1 Million USD | 97.77% |
| 2019 Q3 | 559.61 Thousand USD | -23.09% |
| 2019 Q2 | 727.59 Thousand USD | -65.3% |
| 2019 FY | 4.49 Million USD | 96.39% |
| 2018 FY | 2.28 Million USD | -86.05% |
| 2018 Q4 | 956 Thousand USD | 79.4% |
| 2018 Q3 | 532.89 Thousand USD | 70.02% |
| 2018 Q1 | 484.5 Thousand USD | -28.35% |
| 2018 Q2 | 313.42 Thousand USD | -35.31% |
| 2017 FY | 16.39 Million USD | 392.96% |
| 2017 Q1 | 628.23 Thousand USD | -63.74% |
| 2017 Q4 | 676.22 Thousand USD | 35.06% |
| 2017 Q3 | 500.7 Thousand USD | -96.6% |
| 2017 Q2 | 14.74 Million USD | 2246.75% |
| 2016 Q1 | 1.08 Million USD | 539.26% |
| 2016 FY | 3.32 Million USD | 176.75% |
| 2016 Q4 | 1.73 Million USD | 438.7% |
| 2016 Q3 | 321.6 Thousand USD | 71.54% |
| 2016 Q2 | 187.47 Thousand USD | -82.71% |
| 2015 Q2 | 105.83 Thousand USD | -88.49% |
| 2015 Q1 | 919.52 Thousand USD | 657.03% |
| 2015 FY | 1.2 Million USD | -96.75% |
| 2015 Q3 | 200.81 Thousand USD | 89.74% |
| 2015 Q4 | 169.66 Thousand USD | -15.51% |
| 2014 Q4 | 121.46 Thousand USD | 318.1% |
| 2014 Q3 | 29.05 Thousand USD | -96.73% |
| 2014 Q2 | 887.76 Thousand USD | 4753.53% |
| 2014 FY | 36.97 Million USD | 44769.35% |
| 2014 Q1 | 18.29 Thousand USD | 19.09% |
| 2013 Q1 | 23.23 Thousand USD | -47.2% |
| 2013 Q2 | 22.72 Thousand USD | -2.18% |
| 2013 Q3 | 21.08 Thousand USD | -7.21% |
| 2013 Q4 | 15.35 Thousand USD | -27.16% |
| 2013 FY | 82.4 Thousand USD | -19.53% |
| 2012 Q3 | 23.65 Thousand USD | 70.68% |
| 2012 Q2 | 13.85 Thousand USD | -33.69% |
| 2012 Q1 | 20.89 Thousand USD | 50.28% |
| 2012 FY | 102.4 Thousand USD | -61.03% |
| 2012 Q4 | 44 Thousand USD | 86.03% |
| 2011 FY | 262.78 Thousand USD | 0.0% |
| 2011 Q1 | 170 Thousand USD | 0.0% |
| 2011 Q2 | 40.9 Thousand USD | -75.94% |
| 2011 Q3 | 35.85 Thousand USD | -12.34% |
| 2011 Q4 | 13.9 Thousand USD | -61.21% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acutus Medical, Inc. | 11.22 Million USD | -1.219% |
| Biotricity, Inc. | 17.18 Million USD | 33.889% |
| Cell MedX Corp. | 313.43 Thousand USD | -3524.69% |
| Dynatronics Corporation | 9.9 Million USD | -14.663% |
| Nemaura Medical Inc. | 7.13 Million USD | -59.142% |
| RetinalGenix Technologies Inc. | 2.08 Million USD | -444.351% |
| Sonendo, Inc. | 68.46 Million USD | 83.406% |
| Telesis Bio, Inc. | 63.48 Million USD | 82.106% |
| Talis Biomedical Corporation | 67.18 Million USD | 83.09% |
| Viveve Medical, Inc. | 22.17 Million USD | 48.763% |